Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Thalidomide × Head & Neck × Clear all

Phase

Phase 2 2 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 4 Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1 Gastrointestinal 1

Conditions

Mouth Neoplasms 1

Interventions

Cisplatin 15 Radiotherapy 7 Fluorouracil 7 pembrolizumab 6 Radiotherapy, Intensity-Modulated 6 Docetaxel 6 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Platinum 4 Paclitaxel 4 1,2-diaminocyclohexaneplatinum II citrate 4 Radiation 3 Cetuximab 3 Carboplatin 3 (225)Ac-DOTA-c(RGDyK) 3 atezolizumab 2 Specimen Handling 2 Iodine-123 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 trametinib 1 toripalimab 1 ponatinib 1 pertuzumab 1 fosbretabulin 1 fluorocholine 1 durvalumab 1 dehydroftorafur 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00934739 2015-02-25

A Study of High-Risk Oral Cavity Cancer

National Health Research Institutes, Taiwan

Phase 2/3 Terminated

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡